2 findings
Time-to-amyloid-positivity
mixedin humans1
Plasma pTau217 is associated with time-to-amyloid-positivity in humans (MAE = 5.2 years, ρ = 0.226).
“At lower cortical amyloid levels (< 30 CL), plasma pTau217 was highly variable (MAE = 5.2 years, ρ = 0.226).”
Humanscortical amyloid levels < 30 CL
AAIC 2025 abstract25 Dec 2025
Amyloid PET positivity
upin humans1
Plasma pTau217 predicts amyloid PET positivity in humans (MAE = 3.5 years; ρ = 0.629).
“Beyond 30 CL, plasma and PET estimates of time‐to‐positivity correlated well (MAE = 3.5 years; ρ = 0.629)”
Humanscortical amyloid burden > 30 CL
AAIC 2025 abstract25 Dec 2025
Each standard deviation decrease in locus coeruleus intensity was associated with 53% higher odds of testing positive for an Alzheimer's blood marker.Each standard deviation decrease in locus coeruleus intensity was associated with 53% higher odds of testing positive for an Alzheimer's blood marker.
Assays predicted amyloid-beta positivity with AUCs of 0.929 to 0.952, while simulated pTau217 screening cut amyloid PET scans by over 60%.Assays predicted amyloid-beta positivity with AUCs of 0.929 to 0.952, while simulated pTau217 screening cut amyloid PET scans by over 60%.
Using Alzheimer Biomarker Consortium-Down Syndrome data, researchers found combining plasma pTau217 with a cued recall task identifies cognitively stable adults facing…Using Alzheimer Biomarker Consortium-Down Syndrome data, researchers found combining plasma pTau217 with a cued recall task identifies cognitively stable adults facing clinical impairment within seven years.
In 602 discovery and 2,313 validation participants, associations between plasma pTau217 and brain pathology were stronger among people with lower periventricular…In 602 discovery and 2,313 validation participants, associations between plasma pTau217 and brain pathology were stronger among people with lower periventricular diffusivity.